POPULATION PHARMACOKINETICS OF AMIKACIN IN INTENSIVE-CARE UNIT PATIENTS STUDIED BY NPEM ALGORITHM

被引:16
|
作者
DEBORD, J
PESSIS, C
VOULTOURY, JC
MARQUET, P
LOTFI, H
MERLE, L
LACHSATRE, G
机构
[1] HOP DUPUYTREN,SERV PHARMACOL TOXICOL,F-87042 LIMOGES,FRANCE
[2] HOP DUPUYTREN,SERV REANIMAT POLYVALENTE,F-87042 LIMOGES,FRANCE
[3] FAC PHARM LIMOGES,TOXICOL LAB,F-87025 LIMOGES,FRANCE
关键词
AMIKACIN; POPULATION PHARMACOKINETICS; NPEM ALGORITHM; BAYESIAN ESTIMATION; PREDICTIVE PERFORMANCE;
D O I
10.1111/j.1472-8206.1995.tb00266.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The population pharmacokinetics of amikacin was studied in 40 intensive care unit patients (212 plasma concentrations) by NPEM algorithm using a one-compartment model. The population was best characterized by the following pharmacokinetic parameters: renal clearance relative to creatinine clearance (C-s = 0.96 +/- 0.33), and either the total volume of distribution (V-d = 23.9 +/- 7.01) or the volume of distribution relative to body weight (V-s = 0.36 +/- 0.10 l.kg(-1). The volume of distribution was increased with respect to the usual value of 0.25 l.kg(-1). The statistical distribution of these pharmacokinetic parameters was approximately gaussian, with no significant correlation between volume of distribution and clearance. The medians and standard deviations of C-s and V-s were used as reference population values to estimate the pharmacokinetics of amikacin in a second group of 29 patients by the bayesian method, with two blood samples per patient. For each patient, the fitted parameters were able to predict the plasma concentrations of amikacin during the next 72 h with no significant bias and good precision (2.9 mg.l(-1) for peaks and 0.5 mg.l(-1) for troughs). This study confirms the ability of the NPEM algorithm to provide reference population values for use in bayesian monitoring of aminoglycoside therapy.
引用
收藏
页码:57 / 61
页数:5
相关论文
共 50 条
  • [21] Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation
    Pressiat, Claire
    Kudela, Agathe
    De Roux, Quentin
    Khoudour, Nihel
    Alessandri, Claire
    Haouache, Hakim
    Vodovar, Dominique
    Woerther, Paul-Louis
    Hutin, Alice
    Ghaleh, Bijan
    Hulin, Anne
    Mongardon, Nicolas
    PHARMACEUTICS, 2022, 14 (02)
  • [22] Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions
    Arechiga-Alvarado, Norma A.
    Medellin-Garibay, Susanna E.
    Milan-Segovia, Rosa del C.
    Ortiz-Alvarez, Arturo
    Magana-Aquino, Martin
    Romano-Moreno, Silvia
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (05)
  • [23] The Pharmacokinetics of Levetiracetam in Critically Ill Adult Patients: An Intensive Care Unit Clinical Study
    Markantonis, Sophia-Liberty
    Markou, Nikolaos
    Karagkounis, Apostolos
    Koutrafouri, Dionysia
    Stefanatou, Helen
    Kousovista, Rania
    Karalis, Vangelis
    APPLIED SCIENCES-BASEL, 2022, 12 (03):
  • [24] Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: A prospective study in the intensive care unit
    Lin, Xiao-bin
    Huang, Fa
    Tong, Li
    Xia, Yan-zhe
    Wu, Jing-jing
    Li, Jia
    Hu, Xiao-guang
    Liang, Tao
    Liu, Xiao-man
    Zhong, Guo-ping
    Cai, Chang-jie
    Chen, Xiao
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 93 : 345 - 352
  • [25] Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients
    Kato, Hideo
    Parker, Suzanne L.
    Roberts, Jason A.
    Hagihara, Mao
    Asai, Nobuhiro
    Yamagishi, Yuka
    Paterson, David L.
    Mikamo, Hiroshige
    ANTIBIOTICS-BASEL, 2021, 10 (02): : 1 - 13
  • [26] Population pharmacokinetics of amikacin in pediatric cystic fibrosis patients using a nonlinear mixed effects method
    Caceres Guido, P. A.
    Perez, M.
    Halac, A.
    Ferrari, M.
    Licciardone, N.
    Bramuglia, G.
    Castanos, C.
    Mato, G.
    Porta, A.
    Schaiquevich, P.
    THERAPEUTIC DRUG MONITORING, 2011, 33 (04) : 516 - 516
  • [27] Evaluating amikacin dosage regimens in intensive care unit patients: A pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation
    Zazo, Hinojal
    Martin-Suarez, Ana
    Lanao, Jose M.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 (02) : 155 - 160
  • [28] Personalised pharmacotherapy in intensive care unit patients
    Bellmann, R.
    MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2017, 112 (04) : 289 - 294
  • [29] Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia
    C. Burdet
    O. Pajot
    C. Couffignal
    L. Armand-Lefèvre
    A. Foucrier
    C. Laouénan
    M. Wolff
    L. Massias
    F. Mentré
    European Journal of Clinical Pharmacology, 2015, 71 : 75 - 83
  • [30] Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia
    Burdet, C.
    Pajot, O.
    Couffignal, C.
    Armand-Lefevre, L.
    Foucrier, A.
    Laouenan, C.
    Wolff, M.
    Massias, L.
    Mentre, F.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (01) : 75 - 83